Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI-Powered ECGs could spot silent heart disease before It's too late

NCT ID NCT07057466

Diagnosis Sponsor: Imperial College London Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether artificial intelligence (AI) can analyze routine heart tests (ECGs) to find hidden heart problems like weak heart muscle, valve issues, or high lung pressure. About 590 adults without a prior heart disease diagnosis will have ECGs taken with standard machines and wearable devices like smartwatches. The AI's accuracy will be checked against other tests, but its results won't be used for treatment decisions during the study. The goal is to see if this low-cost, non-invasive approach can help catch heart disease early.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 590 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This prospective observational cohort and validation study will recruit 590 unselected patients attending Chelsea and Westminster Hospital NHS Foundation Trust for routine echocardiography as part of their routine clinical care. Patients attending routine echocardiography who satisfy the inclusion and exclusion criteria will be approached before their echocardiography appointment to obtain informed consent to participate in the study.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged 18-90 years * No prior formal diagnosis of HF (including systolic and diastolic dysfunction), PH, or VHD * Ability to provide informed consent Exclusion Criteria: * Severe arrhythmia or unstable cardiovascular disease * Prior formal diagnosis of HF (including systolic and diastolic dysfunction), PH, or VHD * Cardiac implantable electronic device in-situ, including a permanent pacemaker or implantable cardioverter defibrillator * Involvement in current research or recent involvement in any research prior to recruitment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure with preserved ejection fraction (hfpef; diagnosis) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diastolic heart failure disease gastroesophageal reflux disease heart failure heart valve disorder pulmonary hypertension systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure with preserved ejection fraction (hfpef; diagnosis) Heart failure with reduced ejection fraction (hfref; diagnosis) Pulmonary hypertension (diagnosis) Valvular heart disease stenosis and regurgitation (diagnosis)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chelsea and Westminster Hospital

    RECRUITING

    London, United Kingdom

  • Hammersmith Hospital

    RECRUITING

    London, United Kingdom

  • Southmead Hospital

    RECRUITING

    Bristol, United Kingdom

  • St Mary's Hospital

    RECRUITING

    London, United Kingdom

  • West Middlesex University Hospital

    RECRUITING

    London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.